Monopar Therapeutics (NASDAQ:MNPR) Now Covered by Piper Sandler

Piper Sandler assumed coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note published on Friday, Marketbeat Ratings reports. The firm issued an overweight rating and a $72.00 target price on the stock.

Other equities research analysts also recently issued research reports about the company. Rodman & Renshaw started coverage on Monopar Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright lifted their price target on Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $25.35 on Friday. The stock has a market capitalization of $133.80 million, a P/E ratio of -12.87 and a beta of 1.23. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $38.50. The firm’s 50-day moving average is $21.84 and its two-hundred day moving average is $10.70.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. As a group, analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.